Renal and cardiovascular effects of angiotensin-converting enzyme inhibitor plus angiotensin II receptor antagonist therapy in children with proteinuria

Pediatrics

Volumn 118, Issue 3, 2006, Pages

  Lubrano, Riccardo ^a   Soscia, Francesca ^a   Elli, Marco ^b   Ventriglia, Flavia ^a   Raggi, Claudia ^a   Travasso, Elisabetta ^a   Scateni, Simona ^a   Di Maio, Valeria ^a   Versacci, Paolo ^a   Masciangelo, Raffaele ^a   Romero, Stefano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Angiotensin ii receptor antagonist; Angiotensin converting enzyme inhibitors; Chronic kidney disease; Left ventricular hypertrophy; Proteinuria

Indexed keywords

ENALAPRIL; LOSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR EFFECT; CHILD; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE WALL; HEART VENTRICLE SEPTUM; HUMAN; HYPERTENSION; KIDNEY FUNCTION TEST; MALE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; DRUG COMBINATION; HEART LEFT VENTRICLE HYPERTROPHY; KIDNEY DISEASE; TREATMENT OUTCOME;

ADOLESCENT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHILD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY DISEASES; MALE; PROTEINURIA; TREATMENT OUTCOME;

EID: 33749076289     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2005-2053     Document Type: Article

References (28)

1. Ellis D, Vats A, Morits ML, et al. Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria. J Pediatr. 2003;143:89-97
2. Burton MB, Harris KGP. The role of proteinuria in the progression of chronic renal disease. Am J Kidney Dis. 1996;27:765-775
3. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998;339:1448-1456
4. GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857-1863
5. Soergel M, Schaefer F. Effect of hypertension on the progression of chronic renal failure in children. Am J Hypertens. 2002;15(suppl 1):53-56
6. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med. 1998;318:1657-1666
7. Campbell RC, Ruggenti P, Remuzzi G. Halting the progression of chronic nephropathy. J Am Soc Nephrol. 2002;13(suppl 3):S190-S195
8. Laverman GD, Navis G, Henning RH, et al. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int. 2002;62:1020-1025
9. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int. 2005;67:799-812
10. Wolf G, Butzmann U, Wenzel UO. The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol. 2003;93:P3-P13
11. Ruggenti P, Perna A, Benini R, et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR: investigators of the GISEN Group. J Am Soc Nephrol. 1999;10:997-1006
12. Tikkanen I, Omvik O, Jensen HE. Comparison of the angiotensin II antagonist losartan with the angiotensin-converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens. 1995;13:1343-1351
13. White CT, Macpherson CF, Hurley RM, Matsell DG. Antiproteinuric effects of enalapril and losartan: a pilot study. Pediatr Nephrol. 2003;18:1038-1043
14. Liern M, Dieguez SM, De Reyes V, et al. The additive antiproteinuric effect of enalapril and losartan to normotensive patients with pathology proteinuria [in Spanish]. Nefrologia. 2004;24:553-558
15. Tanaka H, Suzuki K, Nakahata T, et al. Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy. Pediatr Int. 2004;46:576-579
16. Tylicki L, Rutkowski P, Renke M, et al. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis: short term observation. Am J Nephrol. 2002;22:356-362
17. Asai T, Kushiro T, Fujita H, Kammatsuse K. Different effects on cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and/or the angiotensin II type 1 receptor blocker under comparable blood pressure reduction. Hypetens Res. 2005;28:79-87
18. Stawowy P, Margeta C, Blaschke F, et al. Protein kinase C ε mediates angiotensin II-induced activation of β1-integrins in cardiac fibroblasts. Cardiovasc Res. 2005;67:50-59
19. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555-576
20. Bergstein JM. A practical approach to proteinuria. Pediatr Nephrol. 1999;13:697-700
21. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2000;284:3043-3045
22. Ganservoort RT, De Zeeuw D, De Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int. 1989;36:272-279
23. Renke M, Tylicki L, Rutkowski P, et al. Low-dose blockade of renin-angiotensin system improves tubular status in non-diabetic proteinuric patients. Scand J Urol Nephrol. 2005;6:511-517
24. He BX, Yu GL, Liang XQ. Effects of losartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in hypertensive rats [in Chinese]. Hunan Yi Ke Da Xue Xue Bao. 2001;26:118-120
25. Devereux RB, Palmieri V, Liu JE, et al. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction Study. J Hypertens. 2002;20:1445-1450
26. Suzuki H, Kanno Y, Kaneko K, et al. Comparison of the effects of angiotensin receptor antagonist, angiotensin-converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy. Ther Apher Dial. 2004;8:320-327
27. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure independent effect. Circulation. 2002;106:672-678
28. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency: the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939-945